Department of Anesthesia and Perioperative Care, University of California San Francisco, 513 Parnassus Ave, S455, San Francisco, CA, 94143, USA.
UCSF Health Informatics, University of California San Francisco, San Francisco, CA, USA.
BMC Anesthesiol. 2022 May 11;22(1):141. doi: 10.1186/s12871-022-01678-6.
The Centers for Disease Control and Prevention's (CDC) March 2016 opioid prescribing guideline did not include prescribing recommendations for surgical pain. Although opioid over-prescription for surgical patients has been well-documented, the potential effects of the CDC guideline on providers' opioid prescribing practices for surgical patients in the United States remains unclear.
We conducted an interrupted time series analysis (ITSA) of 37,009 opioid-naïve adult patients undergoing inpatient surgery from 2013-2019 at an academic medical center. We assessed quarterly changes in the discharge opioid prescription days' supply, daily and total doses in oral morphine milligram equivalents (OME), and the proportion of patients requiring opioid refills within 30 days of discharge.
The discharge opioid prescription declined by -0.021 (95% CI, -0.045 to 0.003) days per quarter pre-guideline versus -0.201 (95% CI, -0.223 to -0.179) days per quarter post-guideline (p < 0.0001). Likewise, the mean daily and total doses of the discharge opioid prescription declined by -0.387 (95% CI, -0.661 to -0.112) and -7.124 (95% CI, -9.287 to -4.962) OME per quarter pre-guideline versus -2.307 (95% CI, -2.560 to -2.055) and -20.68 (95% CI, -22.66 to -18.69) OME per quarter post-guideline, respectively (p < 0.0001). Opioid refill prescription rates remained unchanged from baseline.
The release of the CDC opioid guideline was associated with a significant reduction in discharge opioid prescriptions without a concomitant increase in the proportion of surgical patients requiring refills within 30 days. The mean prescription for opioid-naïve surgical patients decreased to less than 3 days' supply and less than 50 OME per day by 2019.
疾病控制与预防中心(CDC)2016 年 3 月的阿片类药物处方指南并未包含手术疼痛的处方建议。尽管手术患者阿片类药物过度处方的情况已得到充分证实,但该指南对美国手术患者的提供者阿片类药物处方实践的潜在影响仍不清楚。
我们对一家学术医疗中心 2013 年至 2019 年间进行的 37009 例阿片类药物初治成年住院手术患者进行了一项截断时间序列分析(ITSA)。我们评估了出院时阿片类药物处方的天数供应、口服吗啡毫克当量(OME)的每日和总剂量以及 30 天内需要阿片类药物补充的患者比例的季度变化。
在指南发布之前,出院时的阿片类药物处方减少了 -0.021 天(95%CI,-0.045 至 0.003)/季度,而在指南发布之后,出院时的阿片类药物处方减少了-0.201 天(95%CI,-0.223 至-0.179)/季度(p<0.0001)。同样,出院时的阿片类药物处方的平均每日和总剂量分别减少了-0.387 OME(95%CI,-0.661 至-0.112)和-7.124 OME(95%CI,-9.287 至-4.962)/季度,而在指南发布之后,出院时的阿片类药物处方的平均每日和总剂量分别减少了-2.307 OME(95%CI,-2.560 至-2.055)和-20.68 OME(95%CI,-22.66 至-18.69)/季度(p<0.0001)。阿片类药物补充处方率与基线相比保持不变。
CDC 阿片类药物指南的发布与出院阿片类药物处方的显著减少相关,而在 30 天内需要补充的手术患者比例没有增加。到 2019 年,阿片类药物初治手术患者的平均处方减少至不足 3 天的供应量和每天少于 50 OME。